| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
20,890,000 |
| Market
Cap: |
37.18(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.59 - $8.51 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Aadi Bioscience is a biopharmaceutical company focused on developing and commercializing precision therapies targeted to rare mutation-driven diseases. Co.'s primary drug product, FYARRO, is nab-sirolimus (sirolimus protein-bound particles for injectable suspension (albumin-bound)) for diseases driven by the mTOR pathway activation through mutations or deletions of specific genes such as Tuberous Sclerosis Complex 1 and 2. FYARRO is licensed to Co. by Abraxis BioScience, LLC, a wholly owned subsidiary of Bristol Myers Squibb Company, for various therapeutic areas including oncology, cardiovascular, and metabolic related diseases.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
122,000 |
248,000 |
500,000 |
584,000 |
| Total Sell Value |
$252,439 |
$623,979 |
$2,056,681 |
$2,685,347 |
| Total People Sold |
1 |
1 |
1 |
1 |
| Total Sell Transactions |
5 |
11 |
27 |
35 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Dalal Anupam |
Director |
– • – |
2021-06-30 |
4 |
A |
$1.52 |
$11,248 |
D/D |
7,400 |
16,959 |
|
- |
|
| Prelack Steven |
Director |
– • – |
2021-06-30 |
4 |
A |
$1.52 |
$18,748 |
D/D |
12,334 |
24,485 |
|
- |
|
| Dalal Anupam |
Director |
– • – |
2021-03-31 |
4 |
A |
$1.54 |
$11,248 |
D/D |
7,290 |
9,559 |
|
- |
|
| Castelein Caley |
Director |
– • – |
2021-03-31 |
4 |
A |
$1.54 |
$11,875 |
D/D |
7,696 |
287,603 |
|
- |
|
| Prelack Steven |
Director |
– • – |
2021-03-31 |
4 |
A |
$1.54 |
$18,749 |
D/D |
12,151 |
12,151 |
|
- |
|
| Cohen Cheryl |
Director |
– • – |
2021-03-31 |
4 |
A |
$1.54 |
$12,375 |
D/D |
8,020 |
8,020 |
|
- |
|
| Dugel Pravin |
Director |
– • – |
2021-03-31 |
4 |
A |
$1.54 |
$9,624 |
D/D |
6,237 |
6,237 |
|
- |
|
| Orbimed Capital Gp V Llc |
10% Owner |
– – • |
2020-12-08 |
4 |
S |
$1.96 |
$41,944 |
I/I |
(21,400) |
0 |
|
46% |
|
| Orbimed Capital Gp V Llc |
10% Owner |
– – • |
2020-12-08 |
4 |
OE |
$0.96 |
$20,544 |
I/I |
21,400 |
21,400 |
|
- |
|
| Marek Regina |
Vice President of FinanceOffic |
• – – |
2019-10-15 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
11,625 |
|
- |
|
| Gardner Joseph H. |
President |
• • – |
2019-07-10 |
4 |
B |
$0.81 |
$4,074 |
D/D |
5,000 |
453,019 |
2.73 |
- |
|
| Gardner Joseph H. |
President |
• • – |
2019-07-03 |
4 |
B |
$0.90 |
$4,485 |
D/D |
5,000 |
448,019 |
2.73 |
- |
|
| Novartis Ag |
10% Owner |
– – • |
2019-04-26 |
4 |
S |
$1.03 |
$142,865 |
I/I |
(138,704) |
4,049,804 |
|
- |
|
| Novartis Ag |
10% Owner |
– – • |
2019-04-25 |
4 |
S |
$1.03 |
$579,989 |
I/I |
(563,096) |
4,188,508 |
|
- |
|
| Novartis Ag |
10% Owner |
– – • |
2019-04-24 |
4 |
S |
$1.03 |
$16,895 |
I/I |
(16,403) |
4,751,604 |
|
- |
|
| Novartis Ag |
10% Owner |
– – • |
2019-04-23 |
4 |
S |
$1.03 |
$28,381 |
I/I |
(27,554) |
4,768,007 |
|
- |
|
| Novartis Ag |
10% Owner |
– – • |
2019-04-22 |
4 |
S |
$0.97 |
$6,887 |
I/I |
(7,100) |
4,795,561 |
|
- |
|
| Novartis Ag |
10% Owner |
– – • |
2019-04-15 |
4 |
S |
$0.99 |
$28,506 |
I/I |
(28,794) |
4,802,661 |
|
- |
|
| Novartis Ag |
10% Owner |
– – • |
2019-04-12 |
4 |
S |
$1.04 |
$32,144 |
I/I |
(30,908) |
4,831,455 |
|
- |
|
| Novartis Ag |
10% Owner |
– – • |
2019-04-11 |
4 |
S |
$1.08 |
$62,033 |
I/I |
(57,438) |
4,862,363 |
|
- |
|
| Novartis Ag |
10% Owner |
– – • |
2019-04-10 |
4 |
S |
$1.09 |
$152,851 |
I/I |
(140,230) |
4,919,801 |
|
- |
|
| Novartis Ag |
10% Owner |
– – • |
2019-04-09 |
4 |
S |
$1.01 |
$33,321 |
I/I |
(32,991) |
5,060,031 |
|
- |
|
| Novartis Ag |
10% Owner |
– – • |
2019-04-08 |
4 |
S |
$1.02 |
$28,076 |
I/I |
(27,525) |
5,093,022 |
|
- |
|
| Novartis Ag |
10% Owner |
– – • |
2019-04-05 |
4 |
S |
$1.02 |
$25,154 |
I/I |
(24,661) |
5,120,547 |
|
- |
|
| Novartis Ag |
10% Owner |
– – • |
2019-04-04 |
4 |
S |
$1.01 |
$48,379 |
I/I |
(47,900) |
5,145,208 |
|
- |
|
138 Records found
|
|
Page 3 of 6 |
|
|
0.10 (5.32%) 
